Clinical trial with barbexaclone, a new anti-epileptic agent

Abstract

A new anti-epileptic agent (barbexaclone) was tried in 48 patients suffering from epilepsy and presenting a total of 67 types of crises. All the patients were considered 'bad cases' because of either the intensity of the epileptic manifestations or their refractoriness to the usual medications. The results, similar to others already published, could be considered as good for grand mal epilepsy both for those convulsions occurring during either sleeping or waking hours and suggest further observations in focal crises. Though not considered as a first line medication in petit mal seizures the drug gave excellent results when used as an adjuvant in the suppression of absences and the annulation of convulsant effects of some drugs used in petit mal. No toxic reactions were noted, and the side effects, which were never very intense, tended to disappear in the majority of cases with continued use of the drug.